Targeting DNA damage response pathways in cancer.

Area of Science:

• Molecular Biology
• Genetics
• Cancer Biology

Background:

• The DNA damage response (DDR) is a complex network of pathways that maintains genomic stability.
• Mutations in DDR genes are common in cancer, leading to genomic instability and influencing tumor progression and treatment response.
• Tumors with BRCA1/BRCA2 mutations, deficient in homologous recombination repair, are sensitive to PARP inhibitors, serving as a model for targeted therapy.

Purpose of the Study:

• To review current strategies for inactivating DDR pathways using small-molecule inhibitors.
• To highlight DDR-targeting compounds currently in clinical evaluation.
• To explore the potential of synthetic-lethal interactions between DDR genes for novel cancer therapies, including overcoming PARP inhibitor resistance.

Main Methods:

• Review of existing literature on DNA damage response pathways and small-molecule inhibitors.
• Analysis of clinical trial data for DDR-targeting agents.
• Discussion of synthetic-lethal interactions within the DDR network.

Main Results:

• DDR gene mutations are prevalent in cancer, contributing to genomic instability.
• PARP inhibitors demonstrate efficacy in homologous recombination-deficient tumors (e.g., BRCA-mutated).
• Emerging synthetic-lethal interactions offer opportunities to target DDR-deficient cancers and overcome treatment resistance.

Conclusions:

• Targeting the DDR network with small-molecule inhibitors is a promising area of cancer therapy.
• Exploiting synthetic lethality between DDR genes can lead to novel therapeutic strategies.
• Clinical development of DDR inhibitors is advancing, with several compounds under evaluation.